Paroxysmal nocturnal haemoglobinuria (PNH) Program in Pharmaceutical Benefits Scheme (PBS) 012-22022230
Expand allThis document outlines details of PBS-subsidised eculizumab, iptacopan, pegcetacoplan and ravulizumab for patients with paroxysmal nocturnal haemoglobinuria (PNH).
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.
On this page:
Paroxysmal nocturnal haemoglobinuria (PNH) C5 inhibitor - eculizumab and ravulizumab quick reference
Paroxysmal nocturnal haemoglobinuria (PNH) - iptacopan and pegcetacoplan quick reference
Paroxysmal nocturnal haemoglobinuria (PNH) C5 inhibitor - eculizumab and ravulizumab quick reference
Table 1
Restrictions | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self-serve |
Initial 1 induction PB327 form | Written Electronic S100: eculizumab ravulizumab | No | OPA | Must be treated by a:
| Yes - delayed assessment due to DPMQ (cost) |
Initial 2 - switching from LSDP-funded eculizumab -(induction dose) PB327 form | Written Electronic S100: ravulizumab | No | OPA | Must be treated by a:
| Yes - delayed assessment due to DPMQ (cost) |
Return - from PBS-subsidised eculizumab -(induction doses) PB327 form | Written Electronic S100: ravulizumab | No | OPA | Must be treated by a:
| Yes - delayed assessment due to DPMQ (cost) |
Return - from PBS-subsidised pegcetacoplan or iptacopan (induction doses) PB327 form | Written Electronic S100: ravulizumab | No | OPA | Must be treated by a:
| Yes - delayed assessment due to DPMQ (cost) |
Initial switching from PBS -subsidised ravulizumab for pregnancy PB327 form | Written Electronic S100: eculizumab | No | OPA | Must be treated by a:
| Yes - delayed assessment due to DPMQ (cost) |
Initial - switching from PBS-subsidised pegcetacoplan or iptacopan for pregnancy (induction doses) PB327 form | Written Electronic S100: eculizumab | No | OPA | Must be treated by a:
| Yes - delayed assessment due to DPMQ (cost) |
Return - from PBS-subsidised pegcetacoplan or iptacopan (induction doses) PB327 form | Written Electronic S100: eculizumab | No | OPA | Must be treated by a:
| Yes - delayed assessment due to DPMQ (cost) |
Balance of Supply (BOS) transition from non-PBS during induction PB327 form | Written Electronic S100: eculizumab | No | OPA | Must be treated by a:
| Yes - delayed assessment due to DPMQ (cost) |
Grandfather - transition from non-PBS PB329 form | Written Electronic S100: eculizumab ravulizumab
| No | OPA | Must be treated by a:
| Yes - delayed assessment due to DPMQ (cost) |
Grandfather - transition from LSDP-funded eculizumab PB329 form | Written Electronic S100: eculizumab | No | OPA | Must be treated by a:
| Yes - delayed assessment due to DPMQ (cost) |
First continuing or Subsequent continuing PB328 form | Written Electronic S100: eculizumab ravulizumab | No | OPA | Must be treated by a:
| Yes - delayed assessment due to DPMQ (cost) |
Paroxysmal nocturnal haemoglobinuria (PNH) - iptacopan and pegcetacoplan quick reference
Table 2
Restrictions | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self-serve |
Initial PB343 form | Written Electronic S85: iptacopan S100: pegcetacoplan | No | OPA | Must be treated by a:
| Yes - delayed assessment due to DPMQ (cost) |
Return PB344 form | Written Electronic S85: iptacopan S100: pegcetacoplan | No | OPA | Must be treated by a:
| Yes - delayed assessment due to DPMQ (cost) |
Grandfather PB345 form | Written Electronic S85: iptacopan S100: pegcetacoplan | No | OPA | Must be treated by a:
| Yes - delayed assessment due to DPMQ (cost) |
First continuing or Subsequent continuing PB344 form | Written Electronic S100: pegcetacoplan | No | OPA | Must be treated by a:
| Yes - delayed assessment due to DPMQ (cost) |
Continuing PB344 form | Written Electronic S85: iptacopan | No | OPA | Must be treated by a:
| Yes - delayed assessment due to DPMQ (cost) |